Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Down 3.6%

Alaunos Therapeutics, Inc. (NASDAQ:TCRT)’s stock price dropped 3.6% during trading on Tuesday . The company traded as low as $1.03 and last traded at $1.07. Approximately 56,281 shares changed hands during mid-day trading, a decline of 65% from the average daily volume of 160,238 shares. The stock had previously closed at $1.11.

Alaunos Therapeutics Stock Performance

The company’s 50 day simple moving average is $1.48 and its two-hundred day simple moving average is $1.54.

Hedge Funds Weigh In On Alaunos Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Fortis Group Advisors LLC acquired a new stake in shares of Alaunos Therapeutics in the first quarter valued at $25,000. Virtu Financial LLC acquired a new position in Alaunos Therapeutics during the 1st quarter worth about $28,000. Finally, Magnolia Capital Advisors LLC bought a new stake in Alaunos Therapeutics during the 3rd quarter worth about $56,000. Institutional investors and hedge funds own 27.72% of the company’s stock.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.